Abbott is promoting the health economics of its Supera Stent for peripheral artery disease, pointing to a yet-to-be-published study which found that the device is cost-effective because it reduces the need for interventions compared to competing therapies, like Medtronic's Protégé bare-metal peripheral stent and In.Pact Admiral drug-coated balloon.
This year's Fierce 15 companies are all working on big ideas such as cutting-edge patient monitoring, smartphone-based imaging, biodegradable valves and vessels, more accurate knee implants, intestinal ablation to treat diabetes, energy-delivering angioplasty balloons, an implantable cell-based pancreas replacement, and connected asthma inhalers as well as the consumerization of health devices and diagnostics.
Abbott once again said at the TCT conference that its drug-eluting bioresorbable Absorb BVS is comparable, or noninferior, to its standard drug-eluting Xience stent, as it seeks FDA approval next year, which would make it the first company to sell a fully bioresorbable stent in the U.S.
The ongoing Transcatheter Cardiovascular Therapeutics conference in San Francisco couldn't be any more timely, with bigwigs Abbott, Edwards, and Medtronic dropping more than $1 billion on the burgeoning transcatheter mitral valve repair/replacement market in recent months.
Many shoebox-sized drugstores in Hong Kong are magnets for mainland Chinese seeking access to cutting-edge oncology and hepatitis C treatments without a prescription because they are either highly expensive or not available at home in the latest twist of cross-border healthcare buying, Bloomberg reports.
University of Cambridge researchers found that in a pair of similar studies, one in children and adolescents and the other in adults, that an artificial pancreas works better to control blood glucose levels in Type 1 diabetics than self-administration of insulin based on continuous glucose monitor (CGM) data.
Big Pharma is going fishing in the Mexican drug market.
Some months ago, Indian regulators posted a notice that a couple of batches of an Abbott cough syrup was defective, that it contained twice the level of codeine is allowed by law. But the episode, which has been going on for about 9 months, is turning out to be less about flaws in the drugmaker's manufacturing practices than about the flaws in India's system of oversight.
Wall Street is taking Abbott's claim that it is not interested in St. Jude Medical at face value, paving the way for speculation about who the drug and devicemaker will buy instead as it seeks to deploy plentiful cash and bulk up in med tech following a wave of industry M&A.
News that Abbott is preparing a $25 billion bid for drugmaker St. Jude Medical hogged the headlines this morning, but in the latest twist, the drug and devicemaker just told Reuters it is not interested in St. Jude.